01:09 , Aug 23, 2019 |  BC Innovations  |  Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

New biological insights and increased recognition from FDA are transforming osteoarthritis from a testing ground for new pain therapies into its own high-priority indication. At least two mechanisms with disease-modifying potential for osteoarthritis (OA) have...
14:48 , Aug 21, 2019 |  BC Innovations  |  Distillery Therapeutics

Bivalent degraders of HCV NS3/4A protease complex for HCV infection

DISEASE CATEGORY: Infectious disease INDICATION: Hepatitis C virus (HCV) Bivalent small molecules targeting the HCV NS3/4A protease complex and CRBN, which recruits E3 ubiquitin ligase and induces proteasomal degradation, could treat HCV. The molecules were...
01:12 , Jun 28, 2019 |  BC Extra  |  Company News

June 27 Company Quick Takes: Zogenix soars; plus Gardasil, Darzalex, Soliris and more

Zogenix shares surge after agreement to resubmit Fintepla NDA  Zogenix Inc. (NASDAQ:ZGNX) closed up $8.24 (21%) to $47.65 on Thursday after the company announced it had reached an agreement with FDA to resubmit its NDA...
00:43 , Jun 14, 2019 |  BC Extra  |  Company News

Tessa forms JV with biohub to bring its cell therapies to China

Tessa is hoping a JV with a Guangzhou biohub will speed access to the company’s virus-specific T cell therapies for cancers prevalent in China. The Singapore-based company, which partnered Thursday with GSGKC to develop and...
23:04 , Jun 6, 2019 |  BC Extra  |  Politics & Policy

New antibiotic treatments focus of reintroduced Senate bill

A bill that would advance research into new treatments for drug-resistant infections, the DISARM Act of 2019, was reintroduced in the Senate this week. The Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act (...
20:52 , May 30, 2019 |  BC Extra  |  Clinical News

May 30 Clinical Quick Takes: Cancer report shows decline in mortality from melanoma; plus Cara, Novartis

Decrease in mortality from melanoma attributed to checkpoint inhibitors  The rate of death due to melanoma of the skin declined by 8.5% per year during 2014-16 among men and 6.3% per year in 2013-16 among...
23:31 , May 28, 2019 |  BC Extra  |  Company News

May 28 Company Quick Takes: Viela finds China partner for rare CNS disorder mAb; plus Santhera, Juvenescence’s Souvien and more

Viela partners with Hansoh on mAb for rare CNS disorder in China  Viela Bio Inc. (Gaithersburg, Md.) granted Hansoh Pharmaceutical Group Co. Ltd. (Lianyungang, China) rights to develop and commercialize Viela's humanized anti-CD19 mAb inebilizumab...
19:33 , May 17, 2019 |  BC Extra  |  Company News

May 17 Company Quick Takes: A trio of FDA approvals; plus Ligand/Cumulus, Revlimid

Takeda's Gattex gets pediatric approval  FDA approved Gattex teduglutide from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) to include treatment of patients age one and older with short bowel syndrome who are dependent on parenteral support,...
19:24 , May 17, 2019 |  BioCentury  |  Product Development

Pushing China to the forefront: When a first-in-China regulatory strategy makes sense

As reforms in China shorten clinical and regulatory timelines for biotechs across the board, the country has a growing chance to become the first stop for regulatory approvals of first-in-class drugs. The decision to do...
21:57 , May 16, 2019 |  BC Extra  |  Company News

Gilead defends Truvada pricing during House hearing

Chairman and CEO Daniel O'Day defended Gilead's pricing of HIV PrEP drug Truvada at a congressional hearing Thursday. Democrats led by House Oversight and Reform Committee Chair Elijah Cummings (D-Md.) pressed O'Day on the price...